Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
News
Sports
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/bb/fb/a2/bbfba272-0a46-fbd0-9bdf-fd551a459a13/mza_10640543685509571355.jpg/600x600bb.jpg
RealPharma: Conversations with Pharma Pathfinders
RealPharma
48 episodes
1 week ago
Show more...
Life Sciences
Health & Fitness,
Medicine,
Science
RSS
All content for RealPharma: Conversations with Pharma Pathfinders is the property of RealPharma and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Show more...
Life Sciences
Health & Fitness,
Medicine,
Science
https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog20683771/RP_46_artworkb8obo.jpg
Where Policy Meets the Pharmacy Counter
RealPharma: Conversations with Pharma Pathfinders
55 minutes
1 month ago
Where Policy Meets the Pharmacy Counter
  Where Policy Meets the Pharmacy Counter Featuring Congressman Jake Auchincloss Episode SummaryIn this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Congressman Jake Auchincloss (MA-04) to dissect the tangled web of policy, profit, and politics driving America’s drug pricing system. From pharmacy benefit managers (PBMs) to the politics of tariffs, this discussion explores the push for transparency, fair competition, and sustainable reform in healthcare. Auchincloss, a Marine veteran and member of the House Energy and Commerce Committee, brings a rare combination of policy depth and industry fluency. Together, they unpack how entrenched middlemen have distorted the system—and what bipartisan solutions could finally restore balance between innovation and access. What You’ll Learn: Why PBM reform has momentum but keeps stalling in Congress How the Pharmacists Fight Back Act could level the playing field for independent pharmacies The purpose of the Patients Before Monopolies Act and how it targets vertical integration Auchincloss’s vision for a “biotech social contract” that links innovation, IP protection, and insurance design The real story behind drug import tariffs and the risks of chaotic trade policy How U.S. innovation compares to China’s rapidly advancing biotech ecosystem The importance of aligning drug pricing reform with patient access and national competitiveness Memorable Moments: “PBMs deserve to be bulldozed for their behavior over the last two decades.”“There’s no moral hazard in getting sick—no one fakes chemotherapy to get free drugs.”“The most expensive thing in the world is what hasn’t been invented yet.” Why It Matters:As drug costs rise and innovation races ahead, the U.S. faces a defining choice: will healthcare policy reward breakthroughs or bureaucracy? Congressman Auchincloss argues that reform is not just about prices—it’s about preserving America’s leadership in biomedical innovation while ensuring patients can actually access the medicines that save lives. Guest:Congressman Jake AuchinclossU.S. Representative for Massachusetts’ 4th DistrictMember, House Committee on Energy and Commerce Hosts:Na-Ri Oh & Ian Wendt
RealPharma: Conversations with Pharma Pathfinders